transcervical hysteroscopic approach for tubal occlusion with ESSURE and ADRINA devices

Over the past 10 years the transcervical hysteroscopic approach to tubal occlusion has proven to be an excellent option for women seeking permanent contraception. This technique takes advantage of recent innovations, such as miniaturization of endoscopes, continuous flow systems, and advanced cardiovascular technology, to facilitate access and improve the ability to accurately catheterize the fallopian tubes with  the Essure device (Conceptus, Inc) and the Adiana device (Hologic, Inc). (In May 2012, Hologic, Inc withdrew the Adiana Device from the market.) The Essure device has been approved by the US Food and Drug Administration (FDA) since November 2002;